Study guide
8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
Key Takeaways Explain This Topic AI
Beta-blocker (BB) and calcium channel blocker (CCB) overdoses produce severe bradycardia, conduction blocks, and cardiogenic shock; CCB toxicity uniquely produces marked hyperglycemia by inhibiting L-type calcium channels on pancreatic islet beta cells, whereas BB toxicity presents with euglycemia or hypoglycemia.
High-Dose Insulin Euglycemia Therapy (HIET) is the preferred metabolic inotropic therapy, providing regular insulin 1 unit/kg IV bolus followed by 1 to 10 units/kg/h continuous infusion to stimulate myocardial carbohydrate oxidation without increasing myocardial oxygen consumption.
Concentrated dextrose (D10W or D50W) must be co-infused to maintain euglycemia (100–200 mg/dL), and hypokalemia should not be aggressively treated unless serum potassium drops below 2.5–3.0 mEq/L, because total body potassium is conserved and replacement risks severe rebound hyperkalemia.
Intravenous calcium (calcium chloride 1–2 g central or calcium gluconate 3–6 g peripheral) overcomes competitive channel blockade, while glucagon (3–5 mg IV bolus) bypasses beta receptors to elevate cAMP but is limited by tachyphylaxis and severe projectile emesis.
Intravenous Lipid Emulsion 20% (1.5 mL/kg bolus followed by 0.25 mL/kg/min) serves as a third-line rescue therapy for lipophilic cardiotoxin collapse (verapamil, diltiazem, propranolol) via the lipid sink mechanism.
Last updated: October 2026
8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around clinical toxicology and emergency medicine pharmacotherapy principles.
Pathophysiology & Clinical Presentation
Overdoses of cardiovascular medications—specifically calcium channel blockers (CCBs) and beta-adrenergic antagonists (beta-blockers, BBs) —are among the most lethal toxicological emergencies encountered in the emergency department. Both classes induce profound myocardial depression, bradycardia, and refractory vasodilation. CARDIOVASCULAR COLLAPSE: CCB VS. BB OVERDOSE
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ CALCIUM CHANNEL BLOCKERS (CCBs): │
- │ • Non-Dihydropyridines (Verapamil, Diltiazem): Myocardial L-type block │
- │ • Dihydropyridines (Amlodipine, Nifedipine): Vascular smooth muscle block │
- │ • In Overdose: Receptor selectivity is lost; all agents cause severe │
- │ bradycardia, AV nodal block, contractile failure, and vasoplegia │
- │ • Pancreatic Effect: Blocks L-type channels on islet β-cells ──> Halts │
- │ insulin exocytosis ──> PROFOUND HYPERGLYCEMIA │
- ├─────────────────────────────────────────────────────────────────────────────┤
- │ BETA-ADRENERGIC ANTAGONISTS (BBs): │
- │ • Competitive β1/β2 blockade ──> Decreased cAMP & PKA activation │
- │ • Membrane Stabilizing Activity (Propranolol, Acebutolol): Blocks cardiac │
- │ fast Na+ channels ──> QRS widening, ventricular dysrhythmias, seizures │
- │ • Potassium Channel Blockade (Sotalol): Prolongs QTc ──> Torsades │
- │ • High Lipophilicity (Propranolol): Coma, status epilepticus │
- │ • Hepatic Effect: Inhibits glycogenolysis & gluconeogenesis ──> EUGLYCEMIA│
- │ or HYPOGLYCEMIA │
- └─────────────────────────────────────────────────────────────────────────────┘
- The Hallmark Diagnostic Differentiator: Blood Glucose Dynamics
In an undifferentiated patient presenting with profound bradycardia, hypotension, and shock, serum glucose serves as the primary biochemical differentiator between CCB and BB overdoses:
CCB Toxicity : Pancreatic beta-cell insulin secretion is entirely dependent on calcium influx through voltage-gated L-type calcium channels. CCBs block these channels, blunting insulin exocytosis. Coupled with severe shock-induced peripheral insulin resistance, patients exhibit marked hyperglycemia (frequently > 250 – 400 mg/dL >250–400\text{ mg/dL} > 250–400 mg/dL ). The magnitude of hyperglycemia correlates directly with the degree of shock, inotropic depression, and patient mortality.
BB Toxicity : Beta-2 receptor blockade suppresses hepatic glycogenolysis and gluconeogenesis, while pancreatic insulin exocytosis remains unaffected. Consequently, patients present with euglycemia or hypoglycemia .
CCB vs. BB Overdose Diagnostic Matrix
Clinical / Diagnostic Feature Calcium Channel Blocker Overdose Beta-Blocker Overdose
Heart Rate & Conduction Severe sinus bradycardia, sinus arrest, PR prolongation, complete AV block. Severe sinus bradycardia, junctional bradycardia, high-degree AV block.
Blood Pressure Severe refractory hypotension (cardiogenic shock + vasoplegia). Hypotension (predominantly cardiogenic shock; vasodilation with carvedilol/labetalol).
Serum Blood Glucose Profound Hyperglycemia (typically > 250 – 400 mg/dL >250–400\text{ mg/dL} > 250–400 mg/dL ). Euglycemia or Hypoglycemia (inhibition of gluconeogenesis).
ECG QRS Duration Typically normal QRS duration (unless extreme terminal shock). QRS widening with membrane-stabilizing agents (propranolol, acebutolol).
Neurologic Features Mentation remains clear until terminal hypoperfusion. Early coma, delirium, and seizures (high lipophilicity with propranolol).
High-Dose Insulin Euglycemia Therapy (HIET)
High-Dose Insulin Euglycemia Therapy (HIET) has emerged as the first-line, evidence-based metabolic inotropic therapy for severe calcium channel blocker and beta-blocker poisonings refractory to fluid resuscitation.
The Metabolic Switch in Toxic Cardiogenic Shock
Under normal physiological resting conditions, healthy cardiomyocytes derive 60% to 90% of their energy from free fatty acid (FFA) beta-oxidation , with the remainder supplied by glucose and lactate. However, FFA oxidation requires abundant oxygen. In toxic shock states induced by CCBs or BBs, severe hypoperfusion and cellular hypoxia force the myocardium to switch preferentially to carbohydrate (glucose) oxidation , which generates significantly more ATP per mole of oxygen consumed.
However, in CCB and BB toxicity, myocyte glucose uptake is crippled:
Hypoinsulinemia (from CCB pancreatic blockade) and severe peripheral insulin resistance starve myocytes of glucose.
Myocytes cannot transport glucose across the sarcolemma.
The myocardium enters an energy-starved state, depleting ATP, impairing calcium handling, and causing contractile arrest.
Pharmacodynamic Mechanisms of HIET
High-dose regular insulin acts as a potent metabolic inotrope through five distinct actions:
GLUT-4 Translocation : Directly stimulates the translocation of glucose transporter 4 (GLUT-4) to the sarcolemma, driving glucose into starved cardiomyocytes.
Pyruvate Dehydrogenase Activation : Stimulates pyruvate dehydrogenase, driving aerobic carbohydrate oxidation and restoring myocardial ATP synthesis.
SERCA Activation : Enhances sarcoplasmic reticulum calcium ATPase (SERCA) activity, increasing intracellular calcium reuptake and availability during systole.
Inotropy without Increased Oxygen Demand : Unlike traditional catecholamines (epinephrine, dopamine), which dramatically elevate myocardial oxygen consumption ( M V O 2 MVO_2 M V O 2 ) and induce malignant ventricular dysrhythmias, insulin enhances stroke volume and inotropy without increasing M V O 2 MVO_2 M V O 2 .
Microvascular Vasodilation : Induces endothelial nitric oxide synthase (eNOS), dilating coronary and systemic microvascular capillary beds, lowering afterload, and restoring systemic perfusion.
- HIET Clinical Dosing & Administration Protocol HIET OPERATIONAL RESUSCITATION PROTOCOL
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ 1. REGULAR INSULIN IV BOLUS: 1 unit/kg IV │
- │ • If Blood Glucose <250 mg/dL: Administer 25–50 g Dextrose (50–100 mL D50│
- │ • If Blood Glucose >=250 mg/dL: HOLD initial dextrose bolus. │
- ├─────────────────────────────────────────────────────────────────────────────┤
- │ 2. REGULAR INSULIN CONTINUOUS INFUSION: 1 unit/kg/hour │
- │ • Rapidly titrate upward every 15–30 minutes by 0.5–1 unit/kg/h. │
- │ • Effective dosing range: 1 to 10 units/kg/hour (doses up to 10 units/kg/│
- │ are safe and often necessary for severe hemodynamic collapse). │
- ├─────────────────────────────────────────────────────────────────────────────┤
- │ 3. DEXTROSE INFUSION & EUGLYCEMIA MAINTENANCE │
- │ • Initiate Concentrated Dextrose (D10W or D50W via central line). │
- │ • Titrate to maintain blood glucose at 100 to 200 mg/dL. │
- │ • Monitor point-of-care glucose every 15–30 min during titration; hourly │
- │ once hemodynamically stable. │
- ├─────────────────────────────────────────────────────────────────────────────┤
- │ 4. POTASSIUM MANAGEMENT: AVOID THE REBOUND TRAP │
- │ • Insulin drives K+ into cells; total body potassium is NOT lost. │
- │ • DO NOT aggressively treat hypokalemia unless K+ falls < 2.5–3.0 mEq/L │
- │ or dysrhythmias develop. │
- │ • Aggressive repletion causes LETHAL REBOUND HYPERKALEMIA upon weaning! │
- └─────────────────────────────────────────────────────────────────────────────┘
Important
HIET has a delayed onset of 30 to 60 minutes before peak hemodynamic inotropic effects manifest. During this initiation window, hemodynamics must be supported with IV calcium boluses, vasopressors (norepinephrine/epinephrine), and glucagon.
Intravenous Calcium, Glucagon & Lipid Emulsion Protocols
While HIET serves as the primary metabolic therapy, acute stabilization relies on targeted adjunctive therapies.
Intravenous Calcium Salts
Intravenous calcium increases the extracellular-to-intracellular concentration gradient, overcoming competitive channel blockade via mass action and driving calcium through unblocked L-type channels to improve contractility and vascular tone.
10% Calcium Chloride ( C a C l 2 CaCl_2 C a C l 2 ) : 1 to 2 grams (10 to 20 mL) slow IV push over 5 to 10 minutes.
Elemental Calcium : Provides 27.2 mg elemental calcium per mL (272 mg, or 13.6 mEq, per 10 mL ampule), about three times the elemental content of gluconate.
Administration : Central venous access is strongly required . Extravasation causes severe chemical thrombophlebitis, calcinosis cutis, and full-thickness skin necrosis.
10% Calcium Gluconate : 3 to 6 grams (30 to 60 mL) slow IV push over 10 to 15 minutes.
Elemental Calcium : Provides 9.3 mg elemental calcium per mL (93 mg, or 4.65 mEq, per 10 mL ampule).
Administration : Preferred agent for peripheral intravenous access due to lower osmolarity.
Repeat Dosing & Monitoring : Boluses may be repeated every 10 to 20 minutes for up to 3 to 4 doses, or maintained as a continuous infusion (Calcium chloride 0.5–1.5 g/h or Calcium gluconate 1–3 g/h). Many toxicologists aim for an ionized calcium of roughly 1.5 to 2 times the upper limit of normal, while watching for hypercalcemia with repeated dosing.
Intravenous Glucagon Therapy
Glucagon is a first-line adjunctive agent specifically for beta-blocker poisoning .
Mechanism : Glucagon binds to specific G-protein-coupled glucagon receptors on the myocardial sarcolemma, activating adenylate cyclase independently of beta-1 adrenergic receptors . This increases intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A, and opens L-type calcium channels, producing positive chronotropic and inotropic effects.
Dosing Protocol :
Loading Dose : 3 to 5 mg IV (or 50 to 100 mcg/kg) administered as a slow IV push over 2 to 3 minutes.
Evaluation : Assess hemodynamic response within 5 to 10 minutes. If heart rate and MAP improve, initiate a continuous infusion at 2 to 5 mg/hour (infusion rate equal to the effective bolus dose per hour).
Critical Limitations :
Rapid Tachyphylaxis : Receptor desensitization commonly occurs within hours, leading to loss of inotropic efficacy.
Severe Emesis : Induces violent nausea and projectile vomiting in > 50 % >50\% > 50% of patients. Always pretreat with an antiemetic (IV ondansetron 4–8 mg) to prevent catastrophic aspiration in obtunded patients.
Hospital Stock Depletion : Most health-system pharmacies carry insufficient vials for extended infusions; glucagon should serve primarily as a bridge while establishing HIET.
Intravenous Lipid Emulsion (ILE 20%)
Intravenous Lipid Emulsion (ILE) is a third-line rescue therapy for lipophilic drug-induced refractory cardiovascular collapse (e.g., verapamil, diltiazem, propranolol, carvedilol) failing HIET, calcium, and high-dose vasopressors.
Mechanisms of Action :
The 'Lipid Sink' Hypothesis : Creates an expanded intravascular lipid emulsion phase that captures and sequesters highly lipophilic drug molecules away from target receptors in the myocardium and vascular smooth muscle.
Metabolic Rescue : Overcomes toxic FFA oxidation inhibition by flooding myocyte mitochondria with energy substrates.
Direct Inotropy & Channel Activation : Increases intracellular calcium and activates voltage-dependent calcium channels directly.
Administration Regimen :
Initial Bolus : 20% Lipid Emulsion 1.5 mL/kg IV bolus administered over 2 to 3 minutes.
Continuous Infusion : Follow immediately with 0.25 mL/kg/min (up to 0.5 mL/kg/min if instability persists) continuous infusion.
Maximum Dose : Cap cumulative 24-hour dose at 10 to 12 mL/kg .
Adverse Effects & Hazards : Severe hypertriglyceridemia, acute necrotizing pancreatitis, acute respiratory distress syndrome (ARDS) from pulmonary fat microemboli, and severe interference with laboratory analyzers (marked lipemia invalidates electrolytes, troponin, and hemoglobin assays).
Vasoactive Support Selection
Norepinephrine : First-line vasopressor for restoring systemic vascular resistance in vasoplegic shock (especially dihydropyridine CCB toxicity), while providing moderate beta-1 inotropic support.
Epinephrine : Preferred inotropic vasopressor when profound cardiogenic bradycardia and contractile failure predominate.